Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26323345 | 0.85 | PRMT5 (0.37) | NPC1RAB9ASMN1; SMN2PRMT5 | |
| SCHEMBL26323315 | 0.80 | CBFB (0.34) | NPC1POLBRAB9ASMN1; SMN2CCR1 | |
| SCHEMBL26327371 | 0.74 | SLC2A1 (0.31) | POLBSMN1; SMN2 | |
| SCHEMBL26323371 | 0.68 | CBFB (0.36) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26323330 | 0.65 | KDR (0.42) | NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL26158811 | 0.62 | METAP2 (0.52) | NPC1RAB9ASMN1; SMN2CCR1CCR5 | |
| SCHEMBL26323321 | 0.62 | KDR (0.39) | NPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL11460146 | 0.60 | NPC1 (0.61) | NPC1POLBRAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL34719 | 0.58 | METAP2 (0.39) | NPC1POLBRAB9ASMN1; SMN2CCR1 | |
| SCHEMBL35032 | 0.58 | CBFB (0.50) | NPC1POLBRAB9ASMN1; SMN2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ADRA2A 3392/4885ADRA2B 3458/4885ADRA2C 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.